Automated CD34+ cell isolation of peripheral blood stem cell apheresis product.

BACKGROUND AIMS Immunomagnetic enrichment of CD34+ hematopoietic "stem" cells (HSCs) using paramagnetic nanobead coupled CD34 antibody and immunomagnetic extraction with the CliniMACS plus system is the standard approach to generating T-cell-depleted stem cell grafts. Their clinical beneficence in selected indications is established. Even though CD34+ selected grafts are typically given in the context of a severely immunosuppressive conditioning with anti-thymocyte globulin or similar, the degree of T-cell depletion appears to affect clinical outcomes and thus in addition to CD34 cell recovery, the degree of T-cell depletion critically describes process quality. An automatic immunomagnetic cell processing system, CliniMACS Prodigy, including a protocol for fully automatic CD34+ cell selection from apheresis products, was recently developed. We performed a formal process validation to support submission of the protocol for CE release, a prerequisite for clinical use of Prodigy CD34+ products. METHODS Granulocyte-colony stimulating factor-mobilized healthy-donor apheresis products were subjected to CD34+ cell selection using Prodigy with clinical reagents and consumables and advanced beta versions of the CD34 selection software. Target and non-target cells were enumerated using sensitive flow cytometry platforms. RESULTS Nine successful clinical-scale CD34+ cell selections were performed. Beyond setup, no operator intervention was required. Prodigy recovered 74 ± 13% of target cells with a viability of 99.9 ± 0.05%. Per 5 × 10E6 CD34+ cells, which we consider a per-kilogram dose of HSCs, products contained 17 ± 3 × 10E3 T cells and 78 ± 22 × 10E3 B cells. CONCLUSIONS The process for CD34 selection with Prodigy is robust and labor-saving but not time-saving. Compared with clinical CD34+ selected products concurrently generated with the predecessor technology, product properties, importantly including CD34+ cell recovery and T-cell contents, were not significantly different. The automatic system is suitable for routine clinical application.

[1]  F. Appelbaum,et al.  Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  L. Kanz,et al.  Clinical Applications of CD34+ Peripheral Blood Progenitor Cells (PBPC) , 2000, Stem cells.

[3]  E. Seifried,et al.  Pediatric apheresis with a novel apheresis device with electronic interface control , 2013, Transfusion.

[4]  E. Seifried,et al.  Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies , 2015, Transfusion.

[5]  David D. Smith,et al.  Impact of graft cell dose on transplant outcomes following unrelated donor allogeneic peripheral blood stem cell transplantation: higher CD34+ cell doses are associated with decreased relapse rates. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  H. Atkins,et al.  Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  F Beaujean,et al.  Methods of CD34+ cell separation: comparative analysis. , 1997, Transfusion Science.

[8]  E. Seifried,et al.  Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G‐CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5‐year follow‐up study , 2013, Vox sanguinis.

[9]  A. Komatsuda,et al.  Clinical Applications of CD34+ Cell‐selected Peripheral Blood Stem Cells , 2003, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[10]  J. Antin,et al.  Hematopoietic stem cell transplantation donor sources in the 21 st century : choosing the ideal donor when a perfect match does not exist , 2014 .

[11]  E. Seifried,et al.  Allogeneic donor peripheral blood “stem cell” apheresis: prospective comparison of two apheresis systems , 2012, Transfusion.

[12]  E. Shpall,et al.  Isolation of CD34-positive hematopoietic progenitor cells. , 1994, ImmunoMethods.

[13]  A. Bosio,et al.  Isolation and enrichment of stem cells. , 2009, Advances in biochemical engineering/biotechnology.

[14]  Stefan Miltenyi,et al.  Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture , 2013 .

[15]  M. Schmidt,et al.  Effects of storage temperature on hematopoietic stability and microbial safety of BM aspirates , 2014, Bone Marrow Transplantation.

[16]  J. Antin,et al.  Hematopoietic stem cell transplantation donor sources in the 21st century: choosing the ideal donor when a perfect match does not exist. , 2014, Blood.

[17]  J. Fish,et al.  Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors. , 2010, Pediatric clinics of North America.

[18]  E. Seifried,et al.  Mobilized allogeneic peripheral stem/progenitor cell apheresis with Spectra Optia v.5·0, a novel, automatic interface‐controlled apheresis system: results from the first feasibility trial , 2011, Vox sanguinis.

[19]  E. Seifried,et al.  Enumeration of viable CD34(+) cells by flow cytometry in blood, bone marrow and cord blood: results of a study of the novel BD™ stem cell enumeration kit. , 2011, Cytotherapy.

[20]  J. Briones,et al.  Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. , 1997, Blood.

[21]  P. Hari,et al.  Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.